B. Riley Predicts Harrow’s Q1 Earnings (NASDAQ:HROW)

Harrow, Inc. (NASDAQ:HROW) – Research analysts at B. Riley issued their Q1 2025 EPS estimates for shares of Harrow in a research report issued on Wednesday, December 4th. B. Riley analyst M. Mamtani expects that the company will post earnings per share of $0.15 for the quarter. B. Riley has a “Buy” rating and a $69.00 price target on the stock. The consensus estimate for Harrow’s current full-year earnings is $0.09 per share. B. Riley also issued estimates for Harrow’s Q2 2025 earnings at $0.25 EPS, Q3 2025 earnings at $0.25 EPS and Q4 2025 earnings at $0.33 EPS.

HROW has been the topic of several other research reports. Craig Hallum raised their price target on shares of Harrow from $45.00 to $65.00 and gave the company a “buy” rating in a research report on Friday, October 4th. Lake Street Capital lifted their target price on shares of Harrow from $45.00 to $55.00 and gave the stock a “buy” rating in a research report on Friday, October 4th.

Harrow Price Performance

Shares of NASDAQ HROW opened at $37.42 on Thursday. Harrow has a fifty-two week low of $9.13 and a fifty-two week high of $59.23. The stock has a market cap of $1.33 billion, a price-to-earnings ratio of -39.81 and a beta of 0.69. The company has a debt-to-equity ratio of 3.23, a quick ratio of 1.44 and a current ratio of 1.55. The firm’s 50-day simple moving average is $47.18 and its 200 day simple moving average is $35.07.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of HROW. Private Capital Management LLC grew its position in shares of Harrow by 7.8% during the 1st quarter. Private Capital Management LLC now owns 3,012,393 shares of the company’s stock valued at $39,854,000 after purchasing an additional 217,896 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Harrow by 1.2% during the 1st quarter. Vanguard Group Inc. now owns 1,829,805 shares of the company’s stock valued at $24,208,000 after purchasing an additional 21,253 shares in the last quarter. State Street Corp grew its position in shares of Harrow by 2.2% during the 3rd quarter. State Street Corp now owns 730,973 shares of the company’s stock valued at $32,865,000 after purchasing an additional 15,554 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Harrow by 0.6% during the 3rd quarter. Geode Capital Management LLC now owns 722,730 shares of the company’s stock valued at $32,500,000 after purchasing an additional 3,960 shares in the last quarter. Finally, Braidwell LP grew its position in shares of Harrow by 47.9% during the 3rd quarter. Braidwell LP now owns 439,638 shares of the company’s stock valued at $19,766,000 after purchasing an additional 142,450 shares in the last quarter. 72.76% of the stock is currently owned by hedge funds and other institutional investors.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.